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Clinical Trial
Glivec Ineffective for In-Stent Restenosis
Imatinib, better known by its brand name Glivec, effectively suppresses chronicmyelogenous leukemia by inhibiting the tyrosine kinase that is produced by the
aberrant Philadelphia chromosome. Imatinib also inhibits two other tyrosine kinases
that have been implicated in the neointimal proliferation that leads to in-stent reste-
nosis (ISR). Blocking these kinases reduced neointima formation in a mouse model of
restenosis. Zohlnhöfer and colleagues randomized patients undergoing angioplasty for
ISR to either two weeks of oral imatinib or placebo. There was no benefit to therapy
seen by either repeat angiography or clinical events. It appears unlikely that oral
inhibitors of the platelet-derived growth factor will be effective for the treatment of ISR.
See page 1999. See figure.
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Interventional Cardiology
Reduced Frequency of Emergency CABG After PCI
Before stents were available, coronary angioplasty was frequently complicated byarterial dissections and abrupt vessel closure resulting in the need for emergency
bypass surgery. Yang and colleagues studied all of the patients who have undergone
percutaneous coronary intervention (PCI) at the Mayo Clinic since 1979 to examine
the trends in the need for emergency surgery. During the pre-stent era, 3% of PCI cases
went to emergency coronary artery bypass grafting (CABG); this rate has dropped
10-fold in the current stent era to 0.3%. This drop has occurred despite the fact that
patients currently undergoing PCI have higher risk profiles. The mortality of patients
referred for emergency CABG remains high at approximately 10%. This study reports
that only 3 out of every 1,000 coronary interventions results in a referral for emergency
CABG and lends credence to the argument that PCI without on-site surgical backup
may be possible. See page 2004. See figure.
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Atherosclerosis Evaluation
by Ultrasound
Using Ultrasound to Identify Vulnerable Plaques
Three papers in this issue use ultrasound modalities to identify atheroscleroticlesions that have thin, fibrous caps overlying large, avascular, hypocellular lipid
cores. These lesions are less mature and more vulnerable to rupture. Watanabe and
colleagues studied the integrated backscatter (IBS) characteristics of carotid lesions. Six
months of moderate lipid lowering with pravastatin increased the echogenicity, sug-
gesting that they are less vulnerable, but did not reduce overall plaque size. A similar
study by Yokoyama and colleagues compared IBS and arterial stiffness in patients
randomized to either fluvastatin or diet. As in the study by Watanabe and colleagues,
fluvastatin increased plaque echogenicity; it also reduced brachial ankle pulse wave
velocity, suggesting that the entire arterial tree was more compliant. The study by
Rodriguez-Granillo and colleagues used a novel intravascular ultrasound (IVUS)
analysis program called IVUS-Virtual Histology that processes the standard output
from a coronary IVUS study with spectral analysis to characterize plaque composition
into four major components (fibrous, fibrolipidic, necrotic core, and calcium). When
comparing non-culprit lesions in patients presenting with either stable or unstable
syndromes, those with unstable syndromes were found to have three times as many
vulnerable lesions. The other two papers both assessed carotid lesion morphology and
its response to short-term statin therapy. These three studies offer fairly simple ultra-
sound techniques to understand the characteristics of vulnerable lesions and to com-
pare interventions that target these lesions. See pages 2022, 2031, and 2038.
See figure.
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Heart Failure
Ultrafiltration for Decompensated Heart Failure
Two articles and an editorial in this issue consider the use of ultrafiltration (UF)instead of, or in addition to, loop diuretics for decompensated heart failure. These
trials were prompted by the availability of a peripherally inserted device that removes
water through a semipermeable membrane. The fluid removal rate is set by the
physician and can range from 100 to 500 ml/h. Bart and colleagues compared 8 h of
UF with standard care in 20 patients presenting with decompensated heart failure.
Patients treated with UF had an average of 4.6 l of fluid removed versus 2.8 l with usual
care; UF was well tolerated overall. Costanzo and colleagues used UF in 20 patients
with decompenstated heart failure and either renal insufficiency or refractoriness to oral
diuretics. An average of 8 l of fluid was removed from each patient with no deteriora-
tion in renal function; there was only one readmission for heart failure over the
subsequent three months, indicating that the benefits appear to persist. An editorial by
Bourge and Tallaj reviews these studies and offers some thoughts on the types of
patients who are likely to benefit from this emerging therapy. See pages 2043,
2047, and 2052. See figure.
